Analyst Price Targets — CAR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 8, 2026 7:51 am | Dan Levy | Barclays | $160.00 | $176.79 | StreetInsider | Barclays Upgrades Avis Budget Group (CAR) to Equalweight |
| May 20, 2026 11:52 am | — | Morgan Stanley | $99.00 | $151.08 | TheFly | Avis Budget price target raised to $99 from $97 at Morgan Stanley |
| May 8, 2026 3:01 pm | Christopher Stathoulopoulos | Susquehanna | $140.00 | $143.89 | TheFly | Avis Budget price target raised to $140 from $105 at Susquehanna |
| May 5, 2026 8:51 am | — | Barclays | $140.00 | $168.30 | TheFly | Avis Budget price target lowered to $140 from $150 at Barclays |
| May 1, 2026 11:19 am | Chris Woronka | Deutsche Bank | $125.00 | $180.67 | TheFly | Avis Budget price target lowered to $125 from $128 at Deutsche Bank |
| April 30, 2026 8:15 pm | — | Jefferies | $160.00 | $180.67 | TheFly | Jefferies downgrades Avis to Hold on 'technical overhangs' |
| February 23, 2026 11:44 am | — | Goldman Sachs | $85.00 | $96.47 | TheFly | Avis Budget price target lowered to $85 from $111 at Goldman Sachs |
| December 8, 2025 10:23 am | — | Morgan Stanley | $142.00 | $134.85 | TheFly | Avis Budget downgraded to Equal Weight from Overweight at Morgan Stanley |
| November 3, 2025 11:32 am | — | Barclays | $120.00 | $136.07 | TheFly | Avis Budget price target lowered to $120 from $150 at Barclays |
| October 29, 2025 11:49 am | Christopher Stathoulopoulos | Susquehanna | $130.00 | $141.27 | TheFly | Avis Budget price target lowered to $130 from $145 at Susquehanna |
Latest News for CAR
BRISBANE, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”), a clinical-stage biotechnology company developing a pipeline of advanced chimeric antigen receptor T-cell (“CAR-T”) product candidates, today announced details of its next-generation in vivo CAR-T platform. The company plans to advance TPST-4003, its lead in vivo CAR-T product candidate, into a first…
PARSIPPANY, N.J., July 13, 2026 (GLOBE NEWSWIRE) -- Avis Budget Group, Inc. (NASDAQ: CAR) announced today that it plans to report its second quarter 2026 financial results after the market close on Tuesday, July 28, 2026, and to host a conference call for institutional investors to discuss these results on Wednesday, July 29, 2026, at 8:30 a.m.
Charles River Laboratories International, Inc. (NYSE: CRL) today announced a collaboration with Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company,
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies broadly to patients with cancer and autoimmune disease, today announced that preliminary clinical data from the Company's off-the-shelf CAR T-cell product candidate,…
Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort 5 will receive 1×10⁷ CAR-positive cells/kg following lymphodepletion SAN JOSE, Calif., July 6, 2026 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CAR.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.